Q-omics provides the consensus-scored TEX261 profile across patient tissues and cancer cell-line models. TEX261 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TEX261 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, TEX261 RNA expression shows 20,228 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, THCA, and ACC as cancer lineages where TEX261 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEX261 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEX261 survival associations across molecular data types. TEX261 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEX261 RNA expression–survival associations across cancer types. High TEX261 expression shows unfavorable associations in KICH, LIHC, UVM, LGG and MESO, but favorable associations in SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for TEX261 RNA expression.
This table summarizes TEX261 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TEX261. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEX261 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, STAD and BLCA. The THCA box plot shows higher TEX261 RNA expression in normal versus tumor tissue (log2 FC = −1.317, t-test p < 0.001).
This table shows molecular features associated with TEX261 in patient tissues and cancer cell lines. In patient samples, TEX261 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TEX261 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
